HRMY — HARMONY BIOSCIENCES HLDGS IN
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying HRMY?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 2 tracked investors who changed their HRMY position last quarter, 0 bought and 2 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime).
- +3 tracked investors reported holding HRMY at their latest filing
- +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
- −2 tracked investors reduced or exited last quarter (1 reduced, 1 sold out)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.
About HARMONY BIOSCIENCES HLDGS IN (HRMY)
HARMONY BIOSCIENCES HLDGS IN (HRMY) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $48M. Across recent filings, tracked investors recorded 2 new positions, 3 increased, 2 reduced, and 2 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in HRMY
How many top investors track HRMY
A small number of top investors own this.
HRMY Ownership Composition
How HARMONY BIOSCIENCES HLDGS IN is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant72.0%
- Macro28.0%
Tracked investors currently reporting HRMY
2 tracked investors have since exited this position — listed separately below.
- Ken GriffinJun 30, 2026Citadel AdvisorsShares319.8KValue$11.6M% Portfolio0.00%
- Izzy EnglanderJun 30, 2026Millennium ManagementShares319.8KValue$11.6M% Portfolio0.00%
- Ray DalioJun 30, 2026Bridgewater AssociatesShares248.6KValue$9.1M% Portfolio0.04%
Previously held HRMY
These investors reported HRMY in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Paul Tudor Jones | Tudor Investment Corp | 38.5K | $1.1M | Mar 31, 2026 |
| Steve Cohen | Point72 Asset Management | 10.1K | $278.4K | Sep 30, 2025 |
Recent activity
- New$5.8MNov 13, 2025
- Increased$8.6M(8.03%)Feb 13, 2026
- Increased$7M(10.06%)May 15, 2026
- Reduced$9.1M(-1.17%)Aug 14, 2026
- New$1.1MAug 14, 2025
- Reduced$278.4K(-70.10%)Nov 14, 2025
- Sold$0(-100.00%)Feb 17, 2026
- Increased$1.1M(33.79%)May 15, 2026
- Sold$0(-100.00%)Aug 14, 2026
Frequently asked questions
- How many institutional investors hold HRMY?
- 3 tracked institutional investors disclosed a position in HRMY (HARMONY BIOSCIENCES HLDGS IN) in their most recent 13F filing.
- Who is the largest institutional holder of HRMY?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in HRMY, valued at $48M.
- Did institutional ownership of HRMY increase or decrease?
- Across recent 13F filings, tracked investors recorded 2 new positions, 3 increased, 2 reduced, and 2 fully exited HRMY.
- Where does this HRMY ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.